AIM Vaccine Co. Ltd. Reports 4.2% Decline in Revenue for H1 2025 Compared to 2024
I'm PortAI, I can summarize articles.
AIM Vaccine Co., Ltd. reported a 4.2% decline in revenue for H1 2025, totaling approximately RMB514.7 million compared to RMB537.2 million in H1 2024. The decrease was primarily due to lower sales of Class II vaccines, which fell from RMB483.1 million to RMB458.8 million. Conversely, Class I vaccine sales increased from RMB54.1 million to RMB55.9 million. The company is focused on enhancing its research and development and optimizing sales efficiency through a centralized marketing model.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments